Fludarabine, Cyclophosphamide, Rituximab, and Stem Cell Transplant In Treating Patients With Severe Systemic Lupus Erythematosus

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Precancerous/Nonmalignant Condition
2		Additional conditions recognized in this trial
			Lupus Erythematosus, Systemic
			Precancerous Conditions
3		More general conditions related to this trial
			Autoimmune Diseases
			Connective Tissue Diseases
			Immune System Diseases
			Neoplasms
4		Interventions listed in this trial
			cyclophosphamide
			filgrastim
			fludarabine phosphate
			methylprednisolone
			rituximab
			immunologic technique
			laboratory biomarker analysis
5		Additional drug interventions recognized in this trial
			Fludarabine
			Fludarabine monophosphate
			Methylprednisolone acetate
			Methylprednisolone Hemisuccinate
			Prednisolone
			Prednisolone acetate
6		More general drug interventions related to this trial
			Alkylating Agents
			Anti-Inflammatory Agents
			Antiemetics
			Antimetabolites
			Antimetabolites, Antineoplastic
			Antineoplastic Agents
			Antineoplastic Agents, Alkylating
			Antineoplastic Agents, Hormonal
			Antirheumatic Agents
			Autonomic Agents
			Central Nervous System Agents
			Gastrointestinal Agents
			Glucocorticoids
			Hormones
			Hormones, Hormone Substitutes, and Hormone Antagonists
			Immunologic Factors
			Immunosuppressive Agents
			Molecular Mechanisms of Pharmacological Action
			Myeloablative Agonists
			Neuroprotective Agents
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Protective Agents
			Therapeutic Uses
7		Sponsors listed in this trial
			National Cancer Institute (NCI)